International Psoriasis Council
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Commentary: Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis
Esteban Dauden-Tello, MD, PhD
Department of Dermatology, Hospital Universitario de la Princesa
Madrid, Spain
PUBLICATION
1. Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis. Sahin e, M Hawro, Weller K, et al. J Eur Acad Dermatol Venereol. 2022 May;36(5):688-697. doi: 10.1111/jdv.17917. Epub 2022 Mar 8. PMID: 35020226.
Why this article was chosen
Commentary
Sleep disorders have a high prevalence in patients with psoriasis and significantly impact their physical and psychological well-being. The relationship between sleep disorders and psoriasis has been analyzed in numerous studies but remains poorly understood, primarily due to potential confounding factors such as pruritus, anxiety, or depression.
In this article, researchers from Berlin and Lübeck (Germany) dive deeper into understanding the impact of sleep disturbances in patients with psoriasis to identify clinical, demographic, and psychological factors. Using validated questionnaires for evaluating sleep and other measurements of quality of life, they compared psoriasis patients with a group of healthy individuals.
The significant findings of their study revealed that the prevalence of sleep disturbances was higher in psoriasis patients, and sleep was more impaired compared to healthy subjects. No association between sleep disturbance and psoriasis severity was observed, although most patients with sleep disturbances had well-controlled mild psoriasis. Other findings include observations that intense pruritus that occurred at bedtime was associated with impaired sleep (probably due to direct interference with sleep). Sleep disturbances were associated with anxiety, depression, and diminished health-related quality of life, particularly in female psoriasis patients. Increased levels of anxiety and depression were the main predictors of sleep impairment (better than pruritus parameters altogether).
The limitation of the current study includes the inability to define a causal relationship between sleep disturbances and their associated factors. However, it does not detract from the merits of this study that helps us better understand sleep disorders in patients with psoriasis, raising the possibility that complementary psychotherapy aimed at reducing anxiety, depression, and psychological distress may help to improve sleep in our patients.
Happify Health and Almirall Partner Together to Launch Claro
Focus on Psoriasis: A Report from the 2022 Society for Investigative Dermatology (SID) Annual Meeting
Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)
Also Read
Commentary: Biomarkers of Disease Progression in Psoriasis: Current State-of-the-Art
In personalized care for patients, psoriasis biomarkers will be highly relevant. At present, various centers have investigated biomarkers and their clinical significance for psoriasis progression. Read commentary from Andrea Chiricozzi, MD, on three recent publications.
Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic
The COVID-19 pandemic has been a significant concern, and vaccination has been crucial worldwide in its combat.
Commentary: IFN-k is a rheostat for development of psoriasiform inflammation
IPC Councilor, Carlo Pincelli, MD, shares his expert opinion on innovative research that connects insights into immunopathogenesis with genetics and modes of action of treatments.
Subscribe to the IPC Newsletter